nodes	percent_of_prediction	percent_of_DWPC	metapath
Paliperidone—HRH1—atherosclerosis	0.448	1	CbGaD
Paliperidone—CYP3A5—Rosuvastatin—atherosclerosis	0.0355	0.125	CbGbCtD
Paliperidone—CYP3A5—Simvastatin—atherosclerosis	0.033	0.116	CbGbCtD
Paliperidone—CYP3A5—Pravastatin—atherosclerosis	0.0323	0.114	CbGbCtD
Paliperidone—CYP3A5—Lovastatin—atherosclerosis	0.0323	0.114	CbGbCtD
Paliperidone—CYP2D6—Niacin—atherosclerosis	0.0256	0.0901	CbGbCtD
Paliperidone—CYP2D6—Simvastatin—atherosclerosis	0.0203	0.0712	CbGbCtD
Paliperidone—CYP2D6—Lovastatin—atherosclerosis	0.0198	0.0697	CbGbCtD
Paliperidone—CYP2D6—Pravastatin—atherosclerosis	0.0198	0.0697	CbGbCtD
Paliperidone—CYP3A4—Rosuvastatin—atherosclerosis	0.0139	0.0487	CbGbCtD
Paliperidone—CYP3A4—Ezetimibe—atherosclerosis	0.0139	0.0487	CbGbCtD
Paliperidone—CYP3A4—Simvastatin—atherosclerosis	0.0129	0.0453	CbGbCtD
Paliperidone—CYP3A4—Pravastatin—atherosclerosis	0.0126	0.0443	CbGbCtD
Paliperidone—CYP3A4—Lovastatin—atherosclerosis	0.0126	0.0443	CbGbCtD
Paliperidone—HTR2A—arteriole—atherosclerosis	0.00231	0.146	CbGeAlD
Paliperidone—Risperidone—HRH1—atherosclerosis	0.00178	0.516	CrCbGaD
Paliperidone—Iloperidone—HRH1—atherosclerosis	0.00167	0.484	CrCbGaD
Paliperidone—HTR2A—vein—atherosclerosis	0.00138	0.0873	CbGeAlD
Paliperidone—HTR1B—artery—atherosclerosis	0.00117	0.074	CbGeAlD
Paliperidone—HTR1D—artery—atherosclerosis	0.00113	0.0716	CbGeAlD
Paliperidone—HTR2A—hindlimb—atherosclerosis	0.000914	0.058	CbGeAlD
Paliperidone—HTR1B—blood vessel—atherosclerosis	0.000908	0.0576	CbGeAlD
Paliperidone—HTR1D—blood vessel—atherosclerosis	0.000879	0.0558	CbGeAlD
Paliperidone—HTR2A—appendage—atherosclerosis	0.000784	0.0498	CbGeAlD
Paliperidone—HTR2A—artery—atherosclerosis	0.00056	0.0356	CbGeAlD
Paliperidone—HTR2A—endothelium—atherosclerosis	0.000473	0.0301	CbGeAlD
Paliperidone—HTR1D—connective tissue—atherosclerosis	0.000451	0.0286	CbGeAlD
Paliperidone—HTR2A—blood vessel—atherosclerosis	0.000437	0.0277	CbGeAlD
Paliperidone—HTR1B—cardiovascular system—atherosclerosis	0.000405	0.0257	CbGeAlD
Paliperidone—HTR1D—cardiovascular system—atherosclerosis	0.000392	0.0249	CbGeAlD
Paliperidone—HTR1A—cardiovascular system—atherosclerosis	0.000327	0.0207	CbGeAlD
Paliperidone—ADRA1A—cardiovascular system—atherosclerosis	0.000301	0.0191	CbGeAlD
Paliperidone—HRH1—connective tissue—atherosclerosis	0.000268	0.017	CbGeAlD
Paliperidone—ADRA1A—adipose tissue—atherosclerosis	0.000266	0.0169	CbGeAlD
Paliperidone—ADRA2A—connective tissue—atherosclerosis	0.000263	0.0167	CbGeAlD
Paliperidone—ADRA2C—adipose tissue—atherosclerosis	0.000253	0.0161	CbGeAlD
Paliperidone—Tinnitus—Pravastatin—atherosclerosis	0.000251	0.00165	CcSEcCtD
Paliperidone—Malaise—Lovastatin—atherosclerosis	0.00025	0.00164	CcSEcCtD
Paliperidone—Cardiac disorder—Pravastatin—atherosclerosis	0.00025	0.00164	CcSEcCtD
Paliperidone—Flushing—Pravastatin—atherosclerosis	0.00025	0.00164	CcSEcCtD
Paliperidone—Muscle spasms—Simvastatin—atherosclerosis	0.000249	0.00164	CcSEcCtD
Paliperidone—Vertigo—Lovastatin—atherosclerosis	0.000249	0.00163	CcSEcCtD
Paliperidone—Angioedema—Ezetimibe—atherosclerosis	0.000248	0.00163	CcSEcCtD
Paliperidone—Angiopathy—Niacin—atherosclerosis	0.000248	0.00163	CcSEcCtD
Paliperidone—Leukopenia—Lovastatin—atherosclerosis	0.000248	0.00163	CcSEcCtD
Paliperidone—Chills—Niacin—atherosclerosis	0.000245	0.00161	CcSEcCtD
Paliperidone—Malaise—Ezetimibe—atherosclerosis	0.000245	0.00161	CcSEcCtD
Paliperidone—Vision blurred—Simvastatin—atherosclerosis	0.000244	0.0016	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000243	0.0016	CcSEcCtD
Paliperidone—Tremor—Simvastatin—atherosclerosis	0.000243	0.00159	CcSEcCtD
Paliperidone—Alopecia—Niacin—atherosclerosis	0.000242	0.00159	CcSEcCtD
Paliperidone—Chills—Pravastatin—atherosclerosis	0.000241	0.00159	CcSEcCtD
Paliperidone—Insomnia—Rosuvastatin—atherosclerosis	0.000241	0.00158	CcSEcCtD
Paliperidone—Ill-defined disorder—Simvastatin—atherosclerosis	0.00024	0.00158	CcSEcCtD
Paliperidone—Palpitations—Ezetimibe—atherosclerosis	0.00024	0.00158	CcSEcCtD
Paliperidone—Paraesthesia—Rosuvastatin—atherosclerosis	0.00024	0.00157	CcSEcCtD
Paliperidone—Anaemia—Simvastatin—atherosclerosis	0.00024	0.00157	CcSEcCtD
Paliperidone—Malnutrition—Niacin—atherosclerosis	0.000238	0.00156	CcSEcCtD
Paliperidone—Erythema—Niacin—atherosclerosis	0.000238	0.00156	CcSEcCtD
Paliperidone—Alopecia—Pravastatin—atherosclerosis	0.000238	0.00156	CcSEcCtD
Paliperidone—Cough—Ezetimibe—atherosclerosis	0.000237	0.00156	CcSEcCtD
Paliperidone—Angioedema—Simvastatin—atherosclerosis	0.000237	0.00156	CcSEcCtD
Paliperidone—Myalgia—Lovastatin—atherosclerosis	0.000236	0.00155	CcSEcCtD
Paliperidone—Chest pain—Lovastatin—atherosclerosis	0.000236	0.00155	CcSEcCtD
Paliperidone—Arthralgia—Lovastatin—atherosclerosis	0.000236	0.00155	CcSEcCtD
Paliperidone—Anxiety—Lovastatin—atherosclerosis	0.000235	0.00154	CcSEcCtD
Paliperidone—Dyspepsia—Rosuvastatin—atherosclerosis	0.000235	0.00154	CcSEcCtD
Paliperidone—Hypertension—Ezetimibe—atherosclerosis	0.000235	0.00154	CcSEcCtD
Paliperidone—Flatulence—Niacin—atherosclerosis	0.000234	0.00154	CcSEcCtD
Paliperidone—Malaise—Simvastatin—atherosclerosis	0.000234	0.00153	CcSEcCtD
Paliperidone—Tension—Niacin—atherosclerosis	0.000233	0.00153	CcSEcCtD
Paliperidone—Discomfort—Lovastatin—atherosclerosis	0.000233	0.00153	CcSEcCtD
Paliperidone—Vertigo—Simvastatin—atherosclerosis	0.000233	0.00153	CcSEcCtD
Paliperidone—Leukopenia—Simvastatin—atherosclerosis	0.000232	0.00152	CcSEcCtD
Paliperidone—Myalgia—Ezetimibe—atherosclerosis	0.000231	0.00152	CcSEcCtD
Paliperidone—Chest pain—Ezetimibe—atherosclerosis	0.000231	0.00152	CcSEcCtD
Paliperidone—Arthralgia—Ezetimibe—atherosclerosis	0.000231	0.00152	CcSEcCtD
Paliperidone—Nervousness—Niacin—atherosclerosis	0.000231	0.00152	CcSEcCtD
Paliperidone—Flatulence—Pravastatin—atherosclerosis	0.000231	0.00152	CcSEcCtD
Paliperidone—Dry mouth—Lovastatin—atherosclerosis	0.000231	0.00151	CcSEcCtD
Paliperidone—Tension—Pravastatin—atherosclerosis	0.00023	0.00151	CcSEcCtD
Paliperidone—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.00023	0.00151	CcSEcCtD
Paliperidone—Dysgeusia—Pravastatin—atherosclerosis	0.000229	0.00151	CcSEcCtD
Paliperidone—Muscle spasms—Niacin—atherosclerosis	0.000229	0.0015	CcSEcCtD
Paliperidone—Discomfort—Ezetimibe—atherosclerosis	0.000229	0.0015	CcSEcCtD
Paliperidone—Pain—Rosuvastatin—atherosclerosis	0.000228	0.0015	CcSEcCtD
Paliperidone—Constipation—Rosuvastatin—atherosclerosis	0.000228	0.0015	CcSEcCtD
Paliperidone—Confusional state—Lovastatin—atherosclerosis	0.000228	0.0015	CcSEcCtD
Paliperidone—Nervousness—Pravastatin—atherosclerosis	0.000228	0.00149	CcSEcCtD
Paliperidone—Dry mouth—Ezetimibe—atherosclerosis	0.000226	0.00149	CcSEcCtD
Paliperidone—Anaphylactic shock—Lovastatin—atherosclerosis	0.000226	0.00148	CcSEcCtD
Paliperidone—Muscle spasms—Pravastatin—atherosclerosis	0.000225	0.00148	CcSEcCtD
Paliperidone—Infection—Lovastatin—atherosclerosis	0.000225	0.00148	CcSEcCtD
Paliperidone—Vision blurred—Niacin—atherosclerosis	0.000224	0.00147	CcSEcCtD
Paliperidone—HTR2A—connective tissue—atherosclerosis	0.000224	0.0142	CbGeAlD
Paliperidone—Confusional state—Ezetimibe—atherosclerosis	0.000224	0.00147	CcSEcCtD
Paliperidone—Anaphylactic shock—Ezetimibe—atherosclerosis	0.000222	0.00146	CcSEcCtD
Paliperidone—Thrombocytopenia—Lovastatin—atherosclerosis	0.000221	0.00145	CcSEcCtD
Paliperidone—Vision blurred—Pravastatin—atherosclerosis	0.000221	0.00145	CcSEcCtD
Paliperidone—Chest pain—Simvastatin—atherosclerosis	0.000221	0.00145	CcSEcCtD
Paliperidone—Myalgia—Simvastatin—atherosclerosis	0.000221	0.00145	CcSEcCtD
Paliperidone—Arthralgia—Simvastatin—atherosclerosis	0.000221	0.00145	CcSEcCtD
Paliperidone—Infection—Ezetimibe—atherosclerosis	0.00022	0.00145	CcSEcCtD
Paliperidone—Feeling abnormal—Rosuvastatin—atherosclerosis	0.00022	0.00144	CcSEcCtD
Paliperidone—Anxiety—Simvastatin—atherosclerosis	0.00022	0.00144	CcSEcCtD
Paliperidone—Tremor—Pravastatin—atherosclerosis	0.000219	0.00144	CcSEcCtD
Paliperidone—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000218	0.00143	CcSEcCtD
Paliperidone—Discomfort—Simvastatin—atherosclerosis	0.000218	0.00143	CcSEcCtD
Paliperidone—Nervous system disorder—Ezetimibe—atherosclerosis	0.000217	0.00143	CcSEcCtD
Paliperidone—Angioedema—Niacin—atherosclerosis	0.000217	0.00143	CcSEcCtD
Paliperidone—Ill-defined disorder—Pravastatin—atherosclerosis	0.000217	0.00143	CcSEcCtD
Paliperidone—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000217	0.00143	CcSEcCtD
Paliperidone—Anaemia—Pravastatin—atherosclerosis	0.000217	0.00142	CcSEcCtD
Paliperidone—Anorexia—Lovastatin—atherosclerosis	0.000216	0.00142	CcSEcCtD
Paliperidone—Skin disorder—Ezetimibe—atherosclerosis	0.000215	0.00141	CcSEcCtD
Paliperidone—Angioedema—Pravastatin—atherosclerosis	0.000214	0.00141	CcSEcCtD
Paliperidone—Vertigo—Niacin—atherosclerosis	0.000214	0.0014	CcSEcCtD
Paliperidone—Syncope—Niacin—atherosclerosis	0.000213	0.0014	CcSEcCtD
Paliperidone—Confusional state—Simvastatin—atherosclerosis	0.000213	0.0014	CcSEcCtD
Paliperidone—Leukopenia—Niacin—atherosclerosis	0.000213	0.0014	CcSEcCtD
Paliperidone—Urticaria—Rosuvastatin—atherosclerosis	0.000212	0.00139	CcSEcCtD
Paliperidone—CYP3A5—adipose tissue—atherosclerosis	0.000212	0.0134	CbGeAlD
Paliperidone—Anaphylactic shock—Simvastatin—atherosclerosis	0.000211	0.00139	CcSEcCtD
Paliperidone—Oedema—Simvastatin—atherosclerosis	0.000211	0.00139	CcSEcCtD
Paliperidone—Malaise—Pravastatin—atherosclerosis	0.000211	0.00139	CcSEcCtD
Paliperidone—Abdominal pain—Rosuvastatin—atherosclerosis	0.000211	0.00139	CcSEcCtD
Paliperidone—Vertigo—Pravastatin—atherosclerosis	0.00021	0.00138	CcSEcCtD
Paliperidone—Palpitations—Niacin—atherosclerosis	0.00021	0.00138	CcSEcCtD
Paliperidone—Infection—Simvastatin—atherosclerosis	0.00021	0.00138	CcSEcCtD
Paliperidone—Leukopenia—Pravastatin—atherosclerosis	0.00021	0.00138	CcSEcCtD
Paliperidone—Loss of consciousness—Niacin—atherosclerosis	0.000209	0.00137	CcSEcCtD
Paliperidone—Cough—Niacin—atherosclerosis	0.000208	0.00136	CcSEcCtD
Paliperidone—Thrombocytopenia—Simvastatin—atherosclerosis	0.000207	0.00136	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000206	0.00135	CcSEcCtD
Paliperidone—HRH1—adipose tissue—atherosclerosis	0.000206	0.0131	CbGeAlD
Paliperidone—Insomnia—Lovastatin—atherosclerosis	0.000204	0.00134	CcSEcCtD
Paliperidone—Cough—Pravastatin—atherosclerosis	0.000204	0.00134	CcSEcCtD
Paliperidone—Paraesthesia—Lovastatin—atherosclerosis	0.000203	0.00133	CcSEcCtD
Paliperidone—Myalgia—Niacin—atherosclerosis	0.000203	0.00133	CcSEcCtD
Paliperidone—Arthralgia—Niacin—atherosclerosis	0.000203	0.00133	CcSEcCtD
Paliperidone—Hypertension—Pravastatin—atherosclerosis	0.000202	0.00133	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000202	0.00133	CcSEcCtD
Paliperidone—ADRA2A—adipose tissue—atherosclerosis	0.000202	0.0128	CbGeAlD
Paliperidone—Anorexia—Simvastatin—atherosclerosis	0.000202	0.00132	CcSEcCtD
Paliperidone—Dyspnoea—Lovastatin—atherosclerosis	0.000202	0.00132	CcSEcCtD
Paliperidone—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000201	0.00132	CcSEcCtD
Paliperidone—Insomnia—Ezetimibe—atherosclerosis	0.000201	0.00132	CcSEcCtD
Paliperidone—Myalgia—Pravastatin—atherosclerosis	0.000199	0.00131	CcSEcCtD
Paliperidone—Arthralgia—Pravastatin—atherosclerosis	0.000199	0.00131	CcSEcCtD
Paliperidone—Chest pain—Pravastatin—atherosclerosis	0.000199	0.00131	CcSEcCtD
Paliperidone—Paraesthesia—Ezetimibe—atherosclerosis	0.000199	0.00131	CcSEcCtD
Paliperidone—Dyspepsia—Lovastatin—atherosclerosis	0.000199	0.00131	CcSEcCtD
Paliperidone—Anxiety—Pravastatin—atherosclerosis	0.000199	0.00131	CcSEcCtD
Paliperidone—Dry mouth—Niacin—atherosclerosis	0.000198	0.0013	CcSEcCtD
Paliperidone—Dyspnoea—Ezetimibe—atherosclerosis	0.000198	0.0013	CcSEcCtD
Paliperidone—Discomfort—Pravastatin—atherosclerosis	0.000197	0.00129	CcSEcCtD
Paliperidone—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000197	0.00129	CcSEcCtD
Paliperidone—Decreased appetite—Lovastatin—atherosclerosis	0.000197	0.00129	CcSEcCtD
Paliperidone—Dyspepsia—Ezetimibe—atherosclerosis	0.000195	0.00128	CcSEcCtD
Paliperidone—Fatigue—Lovastatin—atherosclerosis	0.000195	0.00128	CcSEcCtD
Paliperidone—HTR2A—cardiovascular system—atherosclerosis	0.000195	0.0124	CbGeAlD
Paliperidone—Anaphylactic shock—Niacin—atherosclerosis	0.000194	0.00128	CcSEcCtD
Paliperidone—Oedema—Niacin—atherosclerosis	0.000194	0.00128	CcSEcCtD
Paliperidone—Pain—Lovastatin—atherosclerosis	0.000193	0.00127	CcSEcCtD
Paliperidone—Constipation—Lovastatin—atherosclerosis	0.000193	0.00127	CcSEcCtD
Paliperidone—Confusional state—Pravastatin—atherosclerosis	0.000193	0.00127	CcSEcCtD
Paliperidone—Decreased appetite—Ezetimibe—atherosclerosis	0.000193	0.00127	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000193	0.00127	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000191	0.00126	CcSEcCtD
Paliperidone—Asthenia—Rosuvastatin—atherosclerosis	0.000191	0.00126	CcSEcCtD
Paliperidone—Insomnia—Simvastatin—atherosclerosis	0.000191	0.00126	CcSEcCtD
Paliperidone—Anaphylactic shock—Pravastatin—atherosclerosis	0.000191	0.00126	CcSEcCtD
Paliperidone—Oedema—Pravastatin—atherosclerosis	0.000191	0.00126	CcSEcCtD
Paliperidone—Fatigue—Ezetimibe—atherosclerosis	0.000191	0.00126	CcSEcCtD
Paliperidone—Shock—Niacin—atherosclerosis	0.000191	0.00125	CcSEcCtD
Paliperidone—Infection—Pravastatin—atherosclerosis	0.00019	0.00125	CcSEcCtD
Paliperidone—Paraesthesia—Simvastatin—atherosclerosis	0.00019	0.00125	CcSEcCtD
Paliperidone—Constipation—Ezetimibe—atherosclerosis	0.00019	0.00125	CcSEcCtD
Paliperidone—Pain—Ezetimibe—atherosclerosis	0.00019	0.00125	CcSEcCtD
Paliperidone—Tachycardia—Niacin—atherosclerosis	0.00019	0.00124	CcSEcCtD
Paliperidone—Pruritus—Rosuvastatin—atherosclerosis	0.000189	0.00124	CcSEcCtD
Paliperidone—Skin disorder—Niacin—atherosclerosis	0.000189	0.00124	CcSEcCtD
Paliperidone—Dyspnoea—Simvastatin—atherosclerosis	0.000189	0.00124	CcSEcCtD
Paliperidone—Thrombocytopenia—Pravastatin—atherosclerosis	0.000187	0.00123	CcSEcCtD
Paliperidone—ADRA1A—liver—atherosclerosis	0.000186	0.0118	CbGeAlD
Paliperidone—Feeling abnormal—Lovastatin—atherosclerosis	0.000186	0.00122	CcSEcCtD
Paliperidone—Dyspepsia—Simvastatin—atherosclerosis	0.000186	0.00122	CcSEcCtD
Paliperidone—Anorexia—Niacin—atherosclerosis	0.000185	0.00122	CcSEcCtD
Paliperidone—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000185	0.00121	CcSEcCtD
Paliperidone—Decreased appetite—Simvastatin—atherosclerosis	0.000184	0.00121	CcSEcCtD
Paliperidone—Feeling abnormal—Ezetimibe—atherosclerosis	0.000183	0.0012	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000183	0.0012	CcSEcCtD
Paliperidone—Diarrhoea—Rosuvastatin—atherosclerosis	0.000183	0.0012	CcSEcCtD
Paliperidone—Fatigue—Simvastatin—atherosclerosis	0.000182	0.0012	CcSEcCtD
Paliperidone—Anorexia—Pravastatin—atherosclerosis	0.000182	0.0012	CcSEcCtD
Paliperidone—Hypotension—Niacin—atherosclerosis	0.000181	0.00119	CcSEcCtD
Paliperidone—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000181	0.00119	CcSEcCtD
Paliperidone—Pain—Simvastatin—atherosclerosis	0.000181	0.00119	CcSEcCtD
Paliperidone—Constipation—Simvastatin—atherosclerosis	0.000181	0.00119	CcSEcCtD
Paliperidone—Urticaria—Lovastatin—atherosclerosis	0.00018	0.00118	CcSEcCtD
Paliperidone—Body temperature increased—Lovastatin—atherosclerosis	0.000179	0.00117	CcSEcCtD
Paliperidone—Abdominal pain—Lovastatin—atherosclerosis	0.000179	0.00117	CcSEcCtD
Paliperidone—ADRA2C—liver—atherosclerosis	0.000178	0.0113	CbGeAlD
Paliperidone—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000177	0.00116	CcSEcCtD
Paliperidone—Dizziness—Rosuvastatin—atherosclerosis	0.000176	0.00116	CcSEcCtD
Paliperidone—Urticaria—Ezetimibe—atherosclerosis	0.000176	0.00116	CcSEcCtD
Paliperidone—Insomnia—Niacin—atherosclerosis	0.000176	0.00115	CcSEcCtD
Paliperidone—Abdominal pain—Ezetimibe—atherosclerosis	0.000175	0.00115	CcSEcCtD
Paliperidone—Body temperature increased—Ezetimibe—atherosclerosis	0.000175	0.00115	CcSEcCtD
Paliperidone—Paraesthesia—Niacin—atherosclerosis	0.000174	0.00115	CcSEcCtD
Paliperidone—Feeling abnormal—Simvastatin—atherosclerosis	0.000174	0.00114	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000174	0.00114	CcSEcCtD
Paliperidone—Dyspnoea—Niacin—atherosclerosis	0.000173	0.00114	CcSEcCtD
Paliperidone—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000173	0.00114	CcSEcCtD
Paliperidone—Insomnia—Pravastatin—atherosclerosis	0.000173	0.00114	CcSEcCtD
Paliperidone—Somnolence—Niacin—atherosclerosis	0.000173	0.00113	CcSEcCtD
Paliperidone—Paraesthesia—Pravastatin—atherosclerosis	0.000172	0.00113	CcSEcCtD
Paliperidone—Dyspepsia—Niacin—atherosclerosis	0.000171	0.00112	CcSEcCtD
Paliperidone—Dyspnoea—Pravastatin—atherosclerosis	0.00017	0.00112	CcSEcCtD
Paliperidone—Decreased appetite—Niacin—atherosclerosis	0.000169	0.00111	CcSEcCtD
Paliperidone—Dyspepsia—Pravastatin—atherosclerosis	0.000168	0.00111	CcSEcCtD
Paliperidone—Rash—Rosuvastatin—atherosclerosis	0.000168	0.0011	CcSEcCtD
Paliperidone—Dermatitis—Rosuvastatin—atherosclerosis	0.000168	0.0011	CcSEcCtD
Paliperidone—Urticaria—Simvastatin—atherosclerosis	0.000168	0.0011	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Niacin—atherosclerosis	0.000168	0.0011	CcSEcCtD
Paliperidone—Abdominal pain—Simvastatin—atherosclerosis	0.000167	0.0011	CcSEcCtD
Paliperidone—Body temperature increased—Simvastatin—atherosclerosis	0.000167	0.0011	CcSEcCtD
Paliperidone—Headache—Rosuvastatin—atherosclerosis	0.000167	0.0011	CcSEcCtD
Paliperidone—Hypersensitivity—Lovastatin—atherosclerosis	0.000167	0.00109	CcSEcCtD
Paliperidone—Decreased appetite—Pravastatin—atherosclerosis	0.000166	0.00109	CcSEcCtD
Paliperidone—Pain—Niacin—atherosclerosis	0.000166	0.00109	CcSEcCtD
Paliperidone—Fatigue—Pravastatin—atherosclerosis	0.000165	0.00108	CcSEcCtD
Paliperidone—Constipation—Pravastatin—atherosclerosis	0.000164	0.00107	CcSEcCtD
Paliperidone—Pain—Pravastatin—atherosclerosis	0.000164	0.00107	CcSEcCtD
Paliperidone—Hypersensitivity—Ezetimibe—atherosclerosis	0.000163	0.00107	CcSEcCtD
Paliperidone—Asthenia—Lovastatin—atherosclerosis	0.000162	0.00107	CcSEcCtD
Paliperidone—Pruritus—Lovastatin—atherosclerosis	0.00016	0.00105	CcSEcCtD
Paliperidone—Asthenia—Ezetimibe—atherosclerosis	0.000159	0.00104	CcSEcCtD
Paliperidone—Gastrointestinal pain—Niacin—atherosclerosis	0.000159	0.00104	CcSEcCtD
Paliperidone—Nausea—Rosuvastatin—atherosclerosis	0.000158	0.00104	CcSEcCtD
Paliperidone—Feeling abnormal—Pravastatin—atherosclerosis	0.000158	0.00103	CcSEcCtD
Paliperidone—Pruritus—Ezetimibe—atherosclerosis	0.000157	0.00103	CcSEcCtD
Paliperidone—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000156	0.00103	CcSEcCtD
Paliperidone—Hypersensitivity—Simvastatin—atherosclerosis	0.000156	0.00102	CcSEcCtD
Paliperidone—Diarrhoea—Lovastatin—atherosclerosis	0.000155	0.00102	CcSEcCtD
Paliperidone—Urticaria—Niacin—atherosclerosis	0.000154	0.00101	CcSEcCtD
Paliperidone—Abdominal pain—Niacin—atherosclerosis	0.000154	0.00101	CcSEcCtD
Paliperidone—Body temperature increased—Niacin—atherosclerosis	0.000154	0.00101	CcSEcCtD
Paliperidone—Urticaria—Pravastatin—atherosclerosis	0.000152	0.000998	CcSEcCtD
Paliperidone—Asthenia—Simvastatin—atherosclerosis	0.000152	0.000997	CcSEcCtD
Paliperidone—Diarrhoea—Ezetimibe—atherosclerosis	0.000152	0.000997	CcSEcCtD
Paliperidone—Abdominal pain—Pravastatin—atherosclerosis	0.000151	0.000993	CcSEcCtD
Paliperidone—Body temperature increased—Pravastatin—atherosclerosis	0.000151	0.000993	CcSEcCtD
Paliperidone—Pruritus—Simvastatin—atherosclerosis	0.00015	0.000983	CcSEcCtD
Paliperidone—Dizziness—Lovastatin—atherosclerosis	0.00015	0.000982	CcSEcCtD
Paliperidone—CYP3A5—liver—atherosclerosis	0.000149	0.00943	CbGeAlD
Paliperidone—Dizziness—Ezetimibe—atherosclerosis	0.000147	0.000963	CcSEcCtD
Paliperidone—Diarrhoea—Simvastatin—atherosclerosis	0.000145	0.00095	CcSEcCtD
Paliperidone—Vomiting—Lovastatin—atherosclerosis	0.000144	0.000944	CcSEcCtD
Paliperidone—Hypersensitivity—Niacin—atherosclerosis	0.000143	0.00094	CcSEcCtD
Paliperidone—Rash—Lovastatin—atherosclerosis	0.000143	0.000936	CcSEcCtD
Paliperidone—Dermatitis—Lovastatin—atherosclerosis	0.000142	0.000935	CcSEcCtD
Paliperidone—Headache—Lovastatin—atherosclerosis	0.000142	0.00093	CcSEcCtD
Paliperidone—Vomiting—Ezetimibe—atherosclerosis	0.000141	0.000926	CcSEcCtD
Paliperidone—Hypersensitivity—Pravastatin—atherosclerosis	0.000141	0.000925	CcSEcCtD
Paliperidone—Dizziness—Simvastatin—atherosclerosis	0.00014	0.000918	CcSEcCtD
Paliperidone—Rash—Ezetimibe—atherosclerosis	0.00014	0.000918	CcSEcCtD
Paliperidone—Dermatitis—Ezetimibe—atherosclerosis	0.00014	0.000917	CcSEcCtD
Paliperidone—Asthenia—Niacin—atherosclerosis	0.000139	0.000915	CcSEcCtD
Paliperidone—Headache—Ezetimibe—atherosclerosis	0.000139	0.000912	CcSEcCtD
Paliperidone—Pruritus—Niacin—atherosclerosis	0.000137	0.000902	CcSEcCtD
Paliperidone—Asthenia—Pravastatin—atherosclerosis	0.000137	0.000901	CcSEcCtD
Paliperidone—Pruritus—Pravastatin—atherosclerosis	0.000135	0.000888	CcSEcCtD
Paliperidone—Vomiting—Simvastatin—atherosclerosis	0.000134	0.000883	CcSEcCtD
Paliperidone—Nausea—Lovastatin—atherosclerosis	0.000134	0.000882	CcSEcCtD
Paliperidone—Rash—Simvastatin—atherosclerosis	0.000133	0.000876	CcSEcCtD
Paliperidone—Dermatitis—Simvastatin—atherosclerosis	0.000133	0.000875	CcSEcCtD
Paliperidone—Diarrhoea—Niacin—atherosclerosis	0.000133	0.000873	CcSEcCtD
Paliperidone—Headache—Simvastatin—atherosclerosis	0.000132	0.00087	CcSEcCtD
Paliperidone—Nausea—Ezetimibe—atherosclerosis	0.000132	0.000865	CcSEcCtD
Paliperidone—Diarrhoea—Pravastatin—atherosclerosis	0.000131	0.000859	CcSEcCtD
Paliperidone—Dizziness—Niacin—atherosclerosis	0.000128	0.000843	CcSEcCtD
Paliperidone—Dizziness—Pravastatin—atherosclerosis	0.000126	0.00083	CcSEcCtD
Paliperidone—Nausea—Simvastatin—atherosclerosis	0.000126	0.000825	CcSEcCtD
Paliperidone—Vomiting—Niacin—atherosclerosis	0.000123	0.000811	CcSEcCtD
Paliperidone—Rash—Niacin—atherosclerosis	0.000122	0.000804	CcSEcCtD
Paliperidone—Dermatitis—Niacin—atherosclerosis	0.000122	0.000803	CcSEcCtD
Paliperidone—Headache—Niacin—atherosclerosis	0.000122	0.000799	CcSEcCtD
Paliperidone—Vomiting—Pravastatin—atherosclerosis	0.000122	0.000798	CcSEcCtD
Paliperidone—Rash—Pravastatin—atherosclerosis	0.000121	0.000792	CcSEcCtD
Paliperidone—HTR2A—liver—atherosclerosis	0.00012	0.00765	CbGeAlD
Paliperidone—Dermatitis—Pravastatin—atherosclerosis	0.00012	0.000791	CcSEcCtD
Paliperidone—Headache—Pravastatin—atherosclerosis	0.00012	0.000787	CcSEcCtD
Paliperidone—Nausea—Niacin—atherosclerosis	0.000115	0.000758	CcSEcCtD
Paliperidone—Nausea—Pravastatin—atherosclerosis	0.000114	0.000746	CcSEcCtD
Paliperidone—CYP3A4—liver—atherosclerosis	0.000112	0.00708	CbGeAlD
Paliperidone—CYP2D6—liver—atherosclerosis	0.00011	0.00697	CbGeAlD
Paliperidone—CYP2D6—Metabolism—GSTM1—atherosclerosis	4.11e-06	4.28e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—F2—atherosclerosis	4.09e-06	4.27e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—INS—atherosclerosis	4.07e-06	4.25e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—CCL2—atherosclerosis	4.07e-06	4.25e-05	CbGpPWpGaD
Paliperidone—DRD3—GPCR downstream signaling—AKT1—atherosclerosis	4.06e-06	4.24e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—INS—atherosclerosis	4.06e-06	4.24e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—ALB—atherosclerosis	4.06e-06	4.24e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—INS—atherosclerosis	4.06e-06	4.23e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling by GPCR—IL6—atherosclerosis	4.06e-06	4.23e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—MAPK3—atherosclerosis	4.03e-06	4.21e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—LPL—atherosclerosis	4.03e-06	4.2e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—CCL2—atherosclerosis	4.01e-06	4.18e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—IGF1—atherosclerosis	4e-06	4.17e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling by GPCR—IL6—atherosclerosis	4e-06	4.17e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—NOS3—atherosclerosis	4e-06	4.17e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—CCL2—atherosclerosis	4e-06	4.17e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—VEGFA—atherosclerosis	3.99e-06	4.16e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—SCARB1—atherosclerosis	3.99e-06	4.16e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—INS—atherosclerosis	3.99e-06	4.16e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—STAT3—atherosclerosis	3.95e-06	4.12e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—IGF1—atherosclerosis	3.94e-06	4.11e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—NOS3—atherosclerosis	3.94e-06	4.11e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—GPX1—atherosclerosis	3.93e-06	4.1e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—IGF1—atherosclerosis	3.93e-06	4.1e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—CCL2—atherosclerosis	3.92e-06	4.09e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—PIK3CG—atherosclerosis	3.91e-06	4.08e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—VEGFA—atherosclerosis	3.91e-06	4.08e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—NOS3—atherosclerosis	3.89e-06	4.05e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—STAT3—atherosclerosis	3.87e-06	4.04e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—IGF1—atherosclerosis	3.86e-06	4.02e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—MMP9—atherosclerosis	3.86e-06	4.02e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—VEGFA—atherosclerosis	3.85e-06	4.01e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—CD36—atherosclerosis	3.83e-06	4e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—NFKB1—atherosclerosis	3.82e-06	3.98e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—STAT3—atherosclerosis	3.81e-06	3.97e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—MMP9—atherosclerosis	3.81e-06	3.97e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—SERPINE1—atherosclerosis	3.8e-06	3.96e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—CXCL8—atherosclerosis	3.8e-06	3.96e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—MAPK3—atherosclerosis	3.78e-06	3.94e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—HMGCR—atherosclerosis	3.77e-06	3.93e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—NFKB1—atherosclerosis	3.77e-06	3.93e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—MAPK8—atherosclerosis	3.75e-06	3.91e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—MAPK3—atherosclerosis	3.75e-06	3.91e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling by GPCR—AKT1—atherosclerosis	3.74e-06	3.9e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—SERPINE1—atherosclerosis	3.74e-06	3.9e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—SERPINE1—atherosclerosis	3.73e-06	3.89e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—ALB—atherosclerosis	3.72e-06	3.88e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—INS—atherosclerosis	3.71e-06	3.86e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—MAPK8—atherosclerosis	3.7e-06	3.86e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—MAPK3—atherosclerosis	3.7e-06	3.86e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling by GPCR—AKT1—atherosclerosis	3.69e-06	3.85e-05	CbGpPWpGaD
Paliperidone—ADRA2B—GPCR downstream signaling—AKT1—atherosclerosis	3.67e-06	3.83e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—CXCL8—atherosclerosis	3.67e-06	3.82e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—TGFB1—atherosclerosis	3.67e-06	3.82e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—SERPINE1—atherosclerosis	3.66e-06	3.82e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—CXCL8—atherosclerosis	3.65e-06	3.8e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CCL2—atherosclerosis	3.65e-06	3.8e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—MAPK3—atherosclerosis	3.64e-06	3.8e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—MTHFR—atherosclerosis	3.63e-06	3.79e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—NOS3—atherosclerosis	3.63e-06	3.78e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling by GPCR—IL6—atherosclerosis	3.61e-06	3.77e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—TGFB1—atherosclerosis	3.59e-06	3.74e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—IGF1—atherosclerosis	3.58e-06	3.74e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—NOS3—atherosclerosis	3.57e-06	3.72e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—NOS3—atherosclerosis	3.56e-06	3.72e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PPARA—atherosclerosis	3.56e-06	3.71e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—NOS3—atherosclerosis	3.56e-06	3.71e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—PTGS2—atherosclerosis	3.55e-06	3.71e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—CXCL8—atherosclerosis	3.55e-06	3.7e-05	CbGpPWpGaD
Paliperidone—HTR1A—GPCR downstream signaling—AKT1—atherosclerosis	3.54e-06	3.69e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—TGFB1—atherosclerosis	3.53e-06	3.68e-05	CbGpPWpGaD
Paliperidone—HTR2C—GPCR downstream signaling—AKT1—atherosclerosis	3.52e-06	3.68e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—NOS3—atherosclerosis	3.5e-06	3.65e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—CXCL8—atherosclerosis	3.49e-06	3.64e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling by GPCR—IL6—atherosclerosis	3.49e-06	3.64e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling by GPCR—IL6—atherosclerosis	3.47e-06	3.62e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—VEGFA—atherosclerosis	3.46e-06	3.61e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—AGT—atherosclerosis	3.45e-06	3.6e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—MMP9—atherosclerosis	3.44e-06	3.58e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—STAT3—atherosclerosis	3.43e-06	3.58e-05	CbGpPWpGaD
Paliperidone—ADRA2C—GPCR downstream signaling—AKT1—atherosclerosis	3.43e-06	3.57e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—VEGFA—atherosclerosis	3.42e-06	3.56e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—SERPINE1—atherosclerosis	3.4e-06	3.55e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—NFKB1—atherosclerosis	3.4e-06	3.54e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—STAT3—atherosclerosis	3.38e-06	3.53e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—APOE—atherosclerosis	3.38e-06	3.52e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling by GPCR—IL6—atherosclerosis	3.37e-06	3.52e-05	CbGpPWpGaD
Paliperidone—ADRA1B—GPCR downstream signaling—AKT1—atherosclerosis	3.37e-06	3.52e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—ABCA1—atherosclerosis	3.36e-06	3.5e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—CAV1—atherosclerosis	3.35e-06	3.49e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—MAPK8—atherosclerosis	3.34e-06	3.48e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—APOA1—atherosclerosis	3.34e-06	3.48e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling by GPCR—AKT1—atherosclerosis	3.33e-06	3.47e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling by GPCR—IL6—atherosclerosis	3.32e-06	3.46e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—MMP9—atherosclerosis	3.32e-06	3.46e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—MMP9—atherosclerosis	3.3e-06	3.44e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—NFKB1—atherosclerosis	3.28e-06	3.42e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—MAPK3—atherosclerosis	3.28e-06	3.42e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—NFKB1—atherosclerosis	3.26e-06	3.4e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—PTGS2—atherosclerosis	3.26e-06	3.4e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—NOS3—atherosclerosis	3.25e-06	3.39e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—MAPK3—atherosclerosis	3.23e-06	3.37e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—MAPK8—atherosclerosis	3.23e-06	3.36e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—CXCL8—atherosclerosis	3.22e-06	3.36e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling by GPCR—AKT1—atherosclerosis	3.22e-06	3.35e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—MMP9—atherosclerosis	3.21e-06	3.35e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—MAPK8—atherosclerosis	3.21e-06	3.35e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling by GPCR—AKT1—atherosclerosis	3.2e-06	3.34e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—TGFB1—atherosclerosis	3.18e-06	3.31e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—NFKB1—atherosclerosis	3.18e-06	3.31e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—CXCL8—atherosclerosis	3.17e-06	3.3e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—CXCL8—atherosclerosis	3.16e-06	3.3e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—MMP9—atherosclerosis	3.16e-06	3.29e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—TGFB1—atherosclerosis	3.14e-06	3.27e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—NFKB1—atherosclerosis	3.13e-06	3.26e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—MAPK8—atherosclerosis	3.12e-06	3.25e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling by GPCR—AKT1—atherosclerosis	3.11e-06	3.25e-05	CbGpPWpGaD
Paliperidone—DRD2—GPCR downstream signaling—AKT1—atherosclerosis	3.11e-06	3.24e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—CXCL8—atherosclerosis	3.1e-06	3.23e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—VEGFA—atherosclerosis	3.09e-06	3.22e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—MAPK8—atherosclerosis	3.07e-06	3.2e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling by GPCR—AKT1—atherosclerosis	3.06e-06	3.19e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—IL6—atherosclerosis	3.06e-06	3.19e-05	CbGpPWpGaD
Paliperidone—HTR2A—GPCR downstream signaling—AKT1—atherosclerosis	3.06e-06	3.19e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—STAT3—atherosclerosis	3.06e-06	3.19e-05	CbGpPWpGaD
Paliperidone—HRH1—GPCR downstream signaling—AKT1—atherosclerosis	3.05e-06	3.18e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PIK3CG—atherosclerosis	3.05e-06	3.18e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—IL6—atherosclerosis	3.01e-06	3.14e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—IL6—atherosclerosis	3.01e-06	3.13e-05	CbGpPWpGaD
Paliperidone—ADRA1A—GPCR downstream signaling—AKT1—atherosclerosis	3e-06	3.12e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—VEGFA—atherosclerosis	2.98e-06	3.11e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—VEGFA—atherosclerosis	2.96e-06	3.09e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—IL6—atherosclerosis	2.95e-06	3.08e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—STAT3—atherosclerosis	2.95e-06	3.08e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PPARG—atherosclerosis	2.94e-06	3.07e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—STAT3—atherosclerosis	2.93e-06	3.06e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—MAPK3—atherosclerosis	2.92e-06	3.04e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—MMP9—atherosclerosis	2.91e-06	3.04e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—INS—atherosclerosis	2.89e-06	3.01e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—HMOX1—atherosclerosis	2.88e-06	3.01e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CXCL8—atherosclerosis	2.88e-06	3.01e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—VEGFA—atherosclerosis	2.88e-06	3.01e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—NFKB1—atherosclerosis	2.88e-06	3e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—MMP9—atherosclerosis	2.87e-06	2.99e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—MMP9—atherosclerosis	2.86e-06	2.98e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—STAT3—atherosclerosis	2.85e-06	2.98e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—VEGFA—atherosclerosis	2.84e-06	2.96e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—NFKB1—atherosclerosis	2.84e-06	2.96e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—MAPK8—atherosclerosis	2.83e-06	2.95e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—TGFB1—atherosclerosis	2.83e-06	2.95e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—NFKB1—atherosclerosis	2.83e-06	2.95e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—AKT1—atherosclerosis	2.82e-06	2.95e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—MAPK3—atherosclerosis	2.82e-06	2.94e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—STAT3—atherosclerosis	2.81e-06	2.93e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—MMP9—atherosclerosis	2.81e-06	2.93e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—MAPK3—atherosclerosis	2.8e-06	2.92e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—MAPK8—atherosclerosis	2.79e-06	2.91e-05	CbGpPWpGaD
Paliperidone—ADRA2A—GPCR downstream signaling—AKT1—atherosclerosis	2.78e-06	2.9e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—MAPK8—atherosclerosis	2.78e-06	2.9e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—AKT1—atherosclerosis	2.78e-06	2.9e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—NFKB1—atherosclerosis	2.78e-06	2.89e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—AKT1—atherosclerosis	2.77e-06	2.89e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—IL6—atherosclerosis	2.76e-06	2.88e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—APOB—atherosclerosis	2.76e-06	2.88e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—IL6—atherosclerosis	2.74e-06	2.86e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—TGFB1—atherosclerosis	2.73e-06	2.85e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—MAPK8—atherosclerosis	2.73e-06	2.85e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—MAPK3—atherosclerosis	2.73e-06	2.84e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—AKT1—atherosclerosis	2.72e-06	2.84e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—TGFB1—atherosclerosis	2.72e-06	2.84e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—IL6—atherosclerosis	2.7e-06	2.82e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—GSTM1—atherosclerosis	2.69e-06	2.8e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—MAPK3—atherosclerosis	2.68e-06	2.8e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—IL6—atherosclerosis	2.66e-06	2.77e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—ALB—atherosclerosis	2.65e-06	2.76e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—TGFB1—atherosclerosis	2.65e-06	2.76e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—LPL—atherosclerosis	2.64e-06	2.75e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—VEGFA—atherosclerosis	2.62e-06	2.73e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—MMP9—atherosclerosis	2.61e-06	2.72e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—TGFB1—atherosclerosis	2.6e-06	2.71e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—STAT3—atherosclerosis	2.59e-06	2.7e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—NFKB1—atherosclerosis	2.58e-06	2.69e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—VEGFA—atherosclerosis	2.57e-06	2.68e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—GPX1—atherosclerosis	2.57e-06	2.68e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—VEGFA—atherosclerosis	2.57e-06	2.68e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—STAT3—atherosclerosis	2.55e-06	2.66e-05	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—AKT1—atherosclerosis	2.55e-06	2.66e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—STAT3—atherosclerosis	2.54e-06	2.65e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—MAPK8—atherosclerosis	2.54e-06	2.64e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—NOS3—atherosclerosis	2.53e-06	2.64e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—AKT1—atherosclerosis	2.53e-06	2.64e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—VEGFA—atherosclerosis	2.52e-06	2.63e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—CD36—atherosclerosis	2.51e-06	2.61e-05	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—AKT1—atherosclerosis	2.49e-06	2.6e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—STAT3—atherosclerosis	2.49e-06	2.6e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—MAPK3—atherosclerosis	2.47e-06	2.58e-05	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—AKT1—atherosclerosis	2.46e-06	2.56e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—MAPK3—atherosclerosis	2.43e-06	2.54e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—MAPK3—atherosclerosis	2.43e-06	2.53e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—TGFB1—atherosclerosis	2.4e-06	2.5e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—IL6—atherosclerosis	2.4e-06	2.5e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—MAPK3—atherosclerosis	2.38e-06	2.49e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—MTHFR—atherosclerosis	2.37e-06	2.48e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—IL6—atherosclerosis	2.36e-06	2.46e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—TGFB1—atherosclerosis	2.36e-06	2.46e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—TGFB1—atherosclerosis	2.36e-06	2.46e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—VEGFA—atherosclerosis	2.34e-06	2.44e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PPARA—atherosclerosis	2.33e-06	2.43e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—STAT3—atherosclerosis	2.32e-06	2.42e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PTGS2—atherosclerosis	2.32e-06	2.41e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—TGFB1—atherosclerosis	2.31e-06	2.41e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—AGT—atherosclerosis	2.26e-06	2.35e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—MAPK3—atherosclerosis	2.21e-06	2.31e-05	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—AKT1—atherosclerosis	2.21e-06	2.3e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—APOE—atherosclerosis	2.21e-06	2.3e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—AKT1—atherosclerosis	2.2e-06	2.29e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—CAV1—atherosclerosis	2.19e-06	2.28e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—APOA1—atherosclerosis	2.18e-06	2.28e-05	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—AKT1—atherosclerosis	2.18e-06	2.27e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—TGFB1—atherosclerosis	2.15e-06	2.24e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—IL6—atherosclerosis	2.13e-06	2.23e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—IL6—atherosclerosis	2.06e-06	2.15e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—IL6—atherosclerosis	2.05e-06	2.14e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PIK3CG—atherosclerosis	1.99e-06	2.08e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—IL6—atherosclerosis	1.99e-06	2.08e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—AKT1—atherosclerosis	1.97e-06	2.05e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—IL6—atherosclerosis	1.96e-06	2.05e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PPARG—atherosclerosis	1.92e-06	2.01e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—AKT1—atherosclerosis	1.9e-06	1.98e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—AKT1—atherosclerosis	1.89e-06	1.97e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—INS—atherosclerosis	1.89e-06	1.97e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—AKT1—atherosclerosis	1.84e-06	1.92e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—AKT1—atherosclerosis	1.81e-06	1.89e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—IL6—atherosclerosis	1.81e-06	1.89e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—AKT1—atherosclerosis	1.79e-06	1.86e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—IL6—atherosclerosis	1.78e-06	1.86e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—IL6—atherosclerosis	1.78e-06	1.85e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—IL6—atherosclerosis	1.74e-06	1.82e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—ALB—atherosclerosis	1.73e-06	1.8e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—AKT1—atherosclerosis	1.67e-06	1.74e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—NOS3—atherosclerosis	1.66e-06	1.73e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—AKT1—atherosclerosis	1.64e-06	1.71e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—AKT1—atherosclerosis	1.64e-06	1.71e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—AKT1—atherosclerosis	1.64e-06	1.71e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—IL6—atherosclerosis	1.62e-06	1.69e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—AKT1—atherosclerosis	1.61e-06	1.68e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PTGS2—atherosclerosis	1.51e-06	1.58e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—AKT1—atherosclerosis	1.49e-06	1.56e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—AKT1—atherosclerosis	1.16e-06	1.21e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—AKT1—atherosclerosis	7.61e-07	7.94e-06	CbGpPWpGaD
